Put companies on watchlist
SINGULUS TECHNOLOGIES AG
ISIN: DE000A1681X5
WKN: A1681X
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SINGULUS TECHNOLOGIES AG · ISIN: DE000A1681X5 · EQS - Company News (46 News)
Country: Germany · Primary market: Germany · EQS NID: 1901929
14 May 2024 08:00AM

SINGULUS TECHNOLOGIES - The MEDLINE Production System for Processing Contact Lenses Continues to Establish itself on the Market


EQS-News: SINGULUS TECHNOLOGIES AG / Key word(s): Disposal
SINGULUS TECHNOLOGIES - The MEDLINE Production System for Processing Contact Lenses Continues to Establish itself on the Market

14.05.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Press Release

SINGULUS TECHNOLOGIES - The MEDLINE Production System for Processing Contact Lenses Continues to Establish itself on the Market

  • Range of applications expanded
  • Capacity of the new machine generation significantly higher
     

Kahl am Main, May 14, 2024 - The MEDLINE production system from SINGULUS TECHNOLOGIES, which was specially developed for the processing of contact lenses, is steadily gaining acceptance in the market. In close cooperation with customers, SINGULUS TECHNOLOGIES has validated the machine technology required for the processing and production of contact lenses in recent months. The existing system concepts have been optimized and customer-specific process and procedure variants have been developed. The systems are developed and manufactured in compliance with all regulatory requirements in order to ensure the highest product quality, to fulfill the regulations of the international health authorities and, in particular, to comply with the relevant standards and specifications of the GMP and GxP/FDA regulations for the industry.

Dr.-Ing. Stefan Rinck, CEO of SINGULUS TECHNOLOGIES, emphasizes the importance of cooperation with key customers: "Our processing systems were specially developed to clean contact lenses of material residues and then coat them. We have now developed systems in which different types of contact lenses, such as daily and monthly disposable lenses, can be reliably processed." Dr. Rinck adds: "In recent weeks, we have received another order for such a production system. This shows that we are meeting the requirements of the market and our customers with our systems."

Background:

SINGULUS TECHNOLOGIES develops wet-chemical processes such as cleaning, etching and deposition for optical substrates made of glass, polymer or monomer components and offers customized machines for surface treatment. The market for contact lenses is a growing sector in the medical technology industry, characterized by increasing consumer demand for contact lenses and their diverse medical applications. With the steady market growth and the innovation dynamics in the area of new products, SINGULUS TECHNOLOGIES sees promising opportunities to continue to play a leading role in this market in the future.

Thin-Film Coating and Surface Treatment

SINGULUS TECHNOLOGIES develops and assembles innovative machines and systems for efficient thin-film coating and surface treatment processes, which are used worldwide in the Photovoltaics, Semiconductor, Medical Technology, Packaging, Glass & Automotive as well as Battery & Hydrogen markets.

The company’s core competencies include various processes of coating technology (PVD sputtering, PECVD, evaporation), surface treatment as well as wet-chemical and thermal production processes. SINGULUS TECHNOLOGIES sees sustainability as an opportunity to position itself with innovative products. In the focus are environmental awareness, efficient use of resources and avoidance of unnecessary CO pollution.

SINGULUS TECHNOLOGIES attaches great importance to responsible and sustainable corporate governance.

SINGULUS TECHNOLOGIES AG, Hanauer Landstraße 103,
D-63796 Kahl/Main, WKN A1681X / ISIN DE000A1681X5

Contact: Bernhard Krause, Corporate Communications, Tel.: +49 (0) 172 833 2224

Maren Schuster, Investor Relations, Tel.: + 49 (0) 160 9609 0279

 

 

 



14.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SINGULUS TECHNOLOGIES AG
Hanauer Landstrasse 103
63796 Kahl am Main
Germany
Phone: +49 (0)1709202924
Fax: +49 (0)6188 440-110
E-mail: bernhard.krause@singulus.de
Internet: www.singulus.de
ISIN: DE000A1681X5, DE000A2AA5H5
WKN: A1681X, A2AA5H
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1901929

 
End of News EQS News Service

1901929  14.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1901929&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - SINGULUS TECHNOLOGIES AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.